ALNA
Allena Pharmaceuticals, Inc.
Set alert
0.08 0.00 0.00%
0.06 Day range 0.1459
52-week range unavailable
- Open
- 0.0641
- Prev close
- 0.075
- Mkt cap
- 9.16M
- Vol
- 252.31M
- Avg vol
- 0
- EPS
- 0.00
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 0.06
- High
- 0.1459
- Forward P/E
- -1.07
- Beta
- 1.15
- Short ratio
- 0.62
- Inst. own
- 7.42%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Aug 15, 2022
- 50-d avg
- 0.124116
- 200-d avg
- 0.276548
- 1y target
- 4.00
Key statistics
- Market cap
- 9.16M
- Enterprise value
- 11.43M
- Trailing P/E
- 0.00
- Forward P/E
- -1.07
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 2.14
- EPS (TTM)
- -0.638
- Beta
- 1.15
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 0.00%
- Revenue (TTM)
- 0
- Revenue growth
- 0.00%
- Free cash flow
- -33.50M
- Total cash
- 6.59M
- Total debt
- 5.28M
- Return on equity
- -541.02%
- Shares outstanding
- 122.08M
- Short % of float
- 8.54%
- 50-day average
- 0.124116
- 200-day average
- 0.276548
Analyst view
Consensus: hold
Hold
Price target (mean) 4.00
Ratings (0m) 4 4 buy · 0 hold · 0 sell
- Strong buy2
- Buy2
- Hold0
- Sell0
- Strong sell0
Next earnings
Aug 15, 2022
Expected Aug 15, 2022. Consensus EPS estimate -0.05.
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Aug 15, 2022 | Jun 1, 2022 | -0.06 | — | — | — |
| May 16, 2022 | Mar 1, 2022 | -0.20 | — | — | — |
| Apr 5, 2022 | Dec 1, 2021 | -0.17 | — | — | — |
| Nov 10, 2021 | Sep 1, 2021 | -0.18 | — | — | — |
| Aug 10, 2021 | Jun 1, 2021 | -0.20 | — | — | — |
| May 11, 2021 | Mar 1, 2021 | -0.21 | — | — | — |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Mar 22, 2022 | B. Riley Securities | down | Buy | Neutral |
| Mar 21, 2022 | HC Wainwright & Co. | down | Buy | Neutral |
| Mar 21, 2022 | Ladenburg Thalmann | down | Buy | Neutral |
| Jun 1, 2020 | HC Wainwright & Co. | init | — | Buy |
| Mar 18, 2020 | B. Riley FBR | main | — | Buy |
| Mar 13, 2020 | B. Riley FBR | main | — | Buy |
About Allena Pharmaceuticals, Inc.
Allena Pharmaceuticals, Inc., a biopharmaceutical company, discovers, develops, and commercializes oral enzyme therapeutics to treat patients with rare and severe metabolic, and kidney disorders in the United States. Its lead product candidate is ALLN-346, a novel and urate degrading enzyme for patients with hyperuricemia and gout in the setting of advanced chronic kidney disease. The company was incorporated in 2011 and is headquartered in Newton, Massachusetts.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- allenapharma.com
News
- Why Korn Ferry Is Trading Lower By Over 8%, Here Are 40 Stocks Moving In Wednesday's Mid-Day Session
- Hot Penny Stocks to Watch Before Market Open on July 29th
- What to Know About Buying Penny Stocks on July 7th
- Alphabet, Dyne Therapeutics And 74 Biggest Movers From Yesterday
- Tesla, Ra Medical Systems And 51 Stocks Moving In Tuesday's Mid-Day Session
- Why Shares Of Allena Pharmaceuticals Are Skyrocketing Today
- ALNA Stock Alert: What to Know as Allena Pharmaceuticals Soars 200%
- What to Know About Buying Penny Stocks on June 29th
- What to Know About Buying Penny Stocks on June 9th
- Trending Penny Stocks to Watch in Early June 2022
Your note
Sign in to keep a note on ALNA — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| BESSEMER VENTURE PARTNERS TRUST | Beneficial Owner of more than 10% of a Class of Security | Purchase | Nov 5, 2017 | 0 |
| BRENNER LOUIS M.D. | Chief Executive Officer | Sale | Nov 14, 2021 | 328,904 |
| FHM VI, L.L.C. | Beneficial Owner of more than 10% of a Class of Security | Purchase | Nov 5, 2017 | 0 |
| HBM BIOCAPITAL II, L.P. | Beneficial Owner of more than 10% of a Class of Security | Purchase | Nov 5, 2017 | 1,638,330 |
| TEPPER ROBERT I | Director and Beneficial Owner of more than 10% of a Class of Security | Purchase | Nov 5, 2017 | 0 |
| THIRD ROCK VENTURES II L P | Beneficial Owner of more than 10% of a Class of Security | Purchase | Nov 5, 2017 | 0 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| TRV GP II, LLC | 2.29% | 2,790,964 | 209.32K | Jun 29, 2022 |
| Vanguard Group, Inc. (The) | 2.20% | 2,682,145 | 201.16K | Jun 29, 2022 |
| Acadian Asset Management. LLC | 1.02% | 1,250,988 | 93.82K | Jun 29, 2022 |
| Frazier Management LLC | 0.95% | 1,019,288 | 76.45K | Mar 30, 2022 |
| Geode Capital Management, LLC | 0.32% | 386,352 | 28.98K | Jun 29, 2022 |
| Two Sigma Securities, LLC | 0.29% | 357,044 | 26.78K | Jun 29, 2022 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 1.62% | 1,972,415 | 147.93K | Jun 29, 2022 |
| Vanguard Extended Market Index Fund | 0.56% | 681,160 | 51.09K | Jun 29, 2022 |
| iShares Core S&P Total U.S. Stock Market ETF | 0.15% | 177,952 | 13.35K | Jul 30, 2022 |
| Fidelity Extended Market Index Fund | 0.15% | 183,607 | 13.77K | Jun 29, 2022 |
| iShares Micro Cap ETF | 0.11% | 122,654 | 9.20K | May 30, 2022 |
| Bridgeway Funds Inc-Ultra Small Company Market Fund | 0.10% | 106,800 | 8.01K | Mar 30, 2022 |